{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/amgen-amgn/",
 "dataUrl": "https://clearank.com/stock/amgen-amgn/data.json",
 "title": "Amgen (AMGN) Stock Forecast & Price Target (2026)",
 "description": "Amgen Inc. (AMGN) stock: Healthcare, Drug Manufacturers - General. $224.2B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Amgen Inc. (AMGN)",
 "published": "2026-06-12T09:10:32+00:00",
 "modified": "2026-09-27T08:41:15.798+00:00",
 "generated": "2026-09-27T15:05:58.937Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "AMGN",
  "name": "Amgen Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "United States",
  "website": "https://www.amgen.com"
 },
 "quote": {
  "price": 414.61,
  "previousClose": 406.04,
  "change": 8.57,
  "changePercent": 2.11,
  "open": 408.25,
  "high": 415.20001,
  "low": 404.19,
  "volume": 2213100,
  "averageVolume": 3365310,
  "marketCap": 224151430186,
  "fiftyTwoWeekHigh": 447.029999,
  "fiftyTwoWeekLow": 269.76999,
  "marketOpen": false,
  "asOf": "2026-09-27T08:41:15.000Z"
 },
 "statistics": {
  "pe": 25.768177,
  "eps": 16.09,
  "dividendYield": 0.024304384041441626,
  "beta": 0.426,
  "priceToSales": 5.8840117,
  "priceToBook": 19.177149,
  "revenueTtm": 38094999552,
  "grossMargin": 0.7204097871493933,
  "returnOnEquity": 0.91473
 },
 "technicals": {
  "rsi": 40.35,
  "macd": -2.42,
  "sma50": 404.7,
  "sma200": 362.12,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bearish",
  "rating": "Neutral"
 },
 "analysis": {
  "rating": "Hold",
  "score": 57,
  "consensus": "Hold",
  "fairValue": 395,
  "analystTarget": 395,
  "analystCount": 33,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-27T08:41:15.000Z",
  "priceAtAnalysis": 414.60999,
  "volatility": {
   "daily": 2.48,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 410.46,
  "aggressiveEntry": 414.61,
  "stopLoss": 393.68,
  "stopLossPercent": 4.09,
  "targets": [
   422.78,
   430.99,
   443.3
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 324.67,
    "base": 448.73,
    "upside90th": 620.21
   },
   {
    "year": 2028,
    "downside10th": 307.3,
    "base": 485.66,
    "upside90th": 767.55
   },
   {
    "year": 2029,
    "downside10th": 300.08,
    "base": 525.64,
    "upside90th": 920.72
   },
   {
    "year": 2030,
    "downside10th": 297.8,
    "base": 568.9,
    "upside90th": 1086.77
   },
   {
    "year": 2031,
    "downside10th": 298.61,
    "base": 615.72,
    "upside90th": 1269.59
   },
   {
    "year": 2032,
    "downside10th": 301.61,
    "base": 666.39,
    "upside90th": 1472.34
   },
   {
    "year": 2033,
    "downside10th": 306.35,
    "base": 721.24,
    "upside90th": 1698.02
   },
   {
    "year": 2034,
    "downside10th": 312.53,
    "base": 780.59,
    "upside90th": 1949.69
   },
   {
    "year": 2035,
    "downside10th": 319.98,
    "base": 844.84,
    "upside90th": 2230.64
   },
   {
    "year": 2036,
    "downside10th": 328.59,
    "base": 914.37,
    "upside90th": 2544.4
   }
  ]
 },
 "faqCount": 8,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "AMGN Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$408.25",
    "Day Range": "$404.19 to $415.20",
    "Prev Close": "$406.04",
    "Volume": "2.21M",
    "52-Week Range": "$269.77 to $447.03",
    "Market Cap": "$224.15B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (-19% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "AMGN Financial Performance",
   "text": [
    "Analysis: In the last 5 quarters, AMGN beat estimates 5 times. The stock rose 4 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "AMGN Analysis",
   "text": [
    "Amgen Inc. (AMGN) is currently trading at $414.61, above its 50-day SMA of $404.70 and its 200-day SMA of $362.12, indicating a generally positive trend. The Relative Strength Index (RSI) is at 40.35, signaling neutral momentum, neither overbought nor oversold. The MACD is currently negative at -2.42, suggesting some bearish pressure in the short term, though it is trading above its 20-day EMA. Key support levels are near the 50-day SMA around $404.70, while resistance may be found near recent highs. Volume has been below average recently, with 2.21 million shares traded compared to a 3.37 million average, indicating a lack of strong conviction from traders. The current technical setup suggests a consolidation phase rather than a strong directional move.",
    "Insiders have sold $30.4 million worth of Amgen Inc. (AMGN) stock, with no reported purchases, indicating a potential lack of confidence in near-term price appreciation.",
    "Recent analyst actions include downgrades from 'Buy' to 'Hold' by HSBC and BMO Capital, reflecting concerns about valuation and limited upside potential.",
    "Amgen Inc. (AMGN) exceeded EPS estimates by 11.92% for the quarter ending June 2026, leading to a positive stock price reaction and demonstrating operational strength.",
    "Wall Street forecasts revenue growth of 6.00% for the current year and 3.00% for the next, indicating steady top-line expansion for Amgen Inc. (AMGN).",
    "Amgen Inc. (AMGN) is expected to maintain its position as a leading biotechnology company, with forward revenue growth projected at 6.00% for the current year and 3.00% for the next. The company's strong profitability and consistent earnings beats provide a solid foundation, but the current 'Hold' consensus and median price target below the current price suggest limited near-term upside potential. The stock's current trading above key moving averages offers some technical support. Future performance will likely depend on the successful development and commercialization of its pipeline drugs and continued execution in its existing therapeutic areas. Key upside catalysts could include positive clinical trial results or unexpected M&A activity, while downside risks include increased competition, regulatory hurdles, or a failure to meet aggressive growth expectations. The high debt-to-equity ratio also warrants monitoring in a rising interest rate environment."
   ],
   "lists": {
    "ProTips": [
     "Given the 'Hold' consensus and median price target below current levels, consider waiting for a more favorable entry point or clearer bullish signals before increasing exposure to Amgen Inc. (AMGN).",
     "Amgen Inc. (AMGN) is trading above its 50-day and 200-day moving averages ($404.70 and $362.12), but with neutral RSI and slightly negative MACD, the technical picture suggests a period of consolidation rather than a strong breakout.",
     "With insider selling dominating recent transactions, it may be prudent to monitor future insider activity closely for any shifts in sentiment that could impact the stock's trajectory."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Signal",
     "text": "Insiders have sold $30.4 million worth of Amgen Inc. (AMGN) stock, with no reported purchases, indicating a potential lack of confidence in near-term price appreciation.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Analyst Downgrades and Price Target Reductions",
     "text": "Recent analyst actions include downgrades from 'Buy' to 'Hold' by HSBC and BMO Capital, reflecting concerns about valuation and limited upside potential.",
     "source": "Analyst Ratings"
    },
    {
     "type": "Bullish",
     "title": "Strong Earnings Beat in Q2 2026",
     "text": "Amgen Inc. (AMGN) exceeded EPS estimates by 11.92% for the quarter ending June 2026, leading to a positive stock price reaction and demonstrating operational strength.",
     "source": "Earnings Report"
    },
    {
     "type": "Neutral",
     "title": "Continued Revenue Growth Projections",
     "text": "Wall Street forecasts revenue growth of 6.00% for the current year and 3.00% for the next, indicating steady top-line expansion for Amgen Inc. (AMGN).",
     "source": "Analyst Estimates"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Amgen Inc. (AMGN) exhibits a price-to-sales ratio of 5.88, which is notably higher than the healthcare sector median of 3.7, suggesting the stock may be trading at a premium. Its earnings per share (EPS) stands at $16.09, with a P/E ratio of 25.77, also appearing elevated compared to the sector average P/E of 31.9, but this needs to be viewed in context of its strong profitability. The company demonstrates exceptional profitability with a net profit margin of 22.95% and a return on equity of 91.47%, significantly outperforming sector averages. However, its debt-to-equity ratio of 4.90 is high, though in line with the sector. While fundamentals are strong, the current valuation and analyst sentiment suggest that the market may be pricing in significant future growth that could be challenging to achieve.",
    "Amgen Inc. (AMGN) most recently reported earnings for the quarter ending June 2026, with an actual EPS of $6.29, beating the estimated $5.62 by 11.92% and leading to a 4.57% price increase. Prior to this, the company missed estimates for the quarter ending December 2025, reporting an EPS of -0.09 against an estimate of -0.33, a 72.73% surprise, which resulted in a 0.32% price change. The company has shown a mixed but generally positive earnings surprise trend over the last few reported quarters, indicating operational resilience.",
    "Amgen Inc. (AMGN) faces the risk of its valuation being too high, as its price-to-sales ratio exceeds the sector median, and the median analyst price target suggests limited upside. Also, insider activity shows a 'Moderate Sell Signal' with $30.4 million in sales versus no reported purchases, indicating a lack of insider confidence in near-term price appreciation. The company's high debt-to-equity ratio of 4.90 also presents a financial risk, especially if interest rates rise or earnings falter."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "224.15B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "25.77"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "16.09"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "2.40%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "447.03"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "269.77"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Neutral RSI Neutral SMA Cross Bullish Price vs SMA Bullish MACD Bearish Golden Cross in effect with the 50-day SMA ($404.70) above the 200-day SMA ($362.12), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "40.35"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-2.42"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "404.70"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "362.12"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.28",
    "Correlation with Nasdaq 100 (QQQ)": "+0.18",
    "Correlation with Bitcoin (BTC)": "-0.07",
    "Correlation with Gold (XAU)": "+0.14"
   }
  },
  {
   "id": "trade-plans",
   "title": "AMGN Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (40.4) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$422.78",
    "TARGET 2": "$430.99",
    "TARGET 3": "$443.30",
    "STOP LOSS": "$393.68"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+1.98%",
    "Average Feb return": "-0.65%",
    "Average Mar return": "-0.78%",
    "Average Apr return": "-0.11%",
    "Average May return": "+1.01%",
    "Average Jun return": "+3.41%",
    "Average Jul return": "+2.08%",
    "Average Aug return": "+2.88%",
    "Average Sep return": "-0.92%",
    "Average Oct return": "-2.35%",
    "Average Nov return": "+2.76%",
    "Average Dec return": "+0.25%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.48%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in AMGN in September 2016 would be worth about $24,157 today, compared with about $35,782 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in AMGN today could grow to about $22,054 by 2036 in the base case, with a bull case near $61,369 and a bear case around $7,925. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "AMGN Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $569 for AMGN by 2030 in the base case, from $415 today (1.4x over 4 years). The downside path ends near $298. These are outcomes of a Monte Carlo simulation run on AMGN's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using AMGN's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "AMGN simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$325",
        "$449",
        "$620"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$307",
        "$486",
        "$768"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$300",
        "$526",
        "$921"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$298",
        "$569",
        "$1,087"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$299",
        "$616",
        "$1,270"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$302",
        "$666",
        "$1,472"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$306",
        "$721",
        "$1,698"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$313",
        "$781",
        "$1,950"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$320",
        "$845",
        "$2,231"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$329",
        "$914",
        "$2,544"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "TLRY Tilray Brands Inc. NASDAQ $4.13 +1.47%",
     "url": "https://clearank.com/stock/tilray-brands-tlry/"
    },
    {
     "text": "VKTX Viking Therapeutics, Inc. NASDAQ $35.56 -3.24%",
     "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
    },
    {
     "text": "DXCM DexCom Inc. NASDAQ $86.62 -0.97%",
     "url": "https://clearank.com/stock/dxcm-stock-analysis/"
    },
    {
     "text": "BSX Boston Scientific Corp. NYSE $43.92 -1.70%",
     "url": "https://clearank.com/stock/boston-scientific-bsx/"
    },
    {
     "text": "CNC Centene Corp. NYSE $61.82 -0.16%",
     "url": "https://clearank.com/stock/centene-cnc/"
    },
    {
     "text": "VRTX Vertex Pharmaceuticals Incorporated NASDAQ $526.19 +0.73%",
     "url": "https://clearank.com/stock/vertex-vrtx/"
    },
    {
     "text": "LLY Eli Lilly and Company NYSE $1,183.46 +0.13%",
     "url": "https://clearank.com/stock/eli-lilly-lly/"
    },
    {
     "text": "OSCR Oscar Health, Inc. NYSE $29.60 +2.53%",
     "url": "https://clearank.com/stock/oscr-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "USB vs PNC Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/usb-vs-pnc/"
    },
    {
     "text": "EOG vs DVN Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/eog-vs-dvn/"
    },
    {
     "text": "VUG vs VOOG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vug-vs-voog/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "AMGN Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$30.4M",
    "Insiders": "22",
    "Avg Transaction": "$2.5M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in AMGN",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Feb 26, 2026",
       "cells": [
        "SANTOS ESTEBAN Officer",
        "Sell",
        "54.8K",
        "$20.8M"
       ]
      },
      {
       "label": "Feb 21, 2025",
       "cells": [
        "REESE DAVID M. Chief Technology Officer",
        "Sell",
        "33.9K",
        "$10.2M"
       ]
      },
      {
       "label": "Feb 7, 2025",
       "cells": [
        "GRAHAM JONATHAN P General Counsel",
        "Sell",
        "25.0K",
        "$7.3M"
       ]
      },
      {
       "label": "May 10, 2022",
       "cells": [
        "GRAHAM JONATHAN P General Counsel",
        "Sell",
        "13.5K",
        "$3.3M"
       ]
      },
      {
       "label": "Aug 30, 2019",
       "cells": [
        "PATTON CYNTHIA M Officer",
        "Sell",
        "13.4K",
        "$2.8M"
       ]
      },
      {
       "label": "Nov 8, 2023",
       "cells": [
        "GRAHAM JONATHAN P General Counsel",
        "Sell",
        "10.0K",
        "$2.7M"
       ]
      },
      {
       "label": "Feb 4, 2021",
       "cells": [
        "GRAHAM JONATHAN P General Counsel",
        "Sell",
        "11.1K",
        "$2.6M"
       ]
      },
      {
       "label": "Feb 11, 2025",
       "cells": [
        "GORDON MURDO Officer",
        "Sell",
        "8.8K",
        "$2.6M"
       ]
      },
      {
       "label": "Feb 19, 2025",
       "cells": [
        "SANTOS ESTEBAN Officer",
        "Sell",
        "8.7K",
        "$2.6M"
       ]
      },
      {
       "label": "Aug 10, 2023",
       "cells": [
        "GORDON MURDO Officer",
        "Sell",
        "9.6K",
        "$2.5M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Amgen+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Amgen Inc.'s current stock price and consensus rating?",
   "answer": "Amgen Inc. (AMGN) is currently trading at $414.61 per share. The consensus rating among analysts is 'Hold', with a consensus score of 57 out of 100."
  },
  {
   "question": "What is the median analyst price target for AMGN stock?",
   "answer": "The median analyst price target for Amgen Inc. (AMGN) is $395.00, which represents a -4.7% downside from its current trading price."
  },
  {
   "question": "How does Amgen Inc.'s valuation compare to its sector peers?",
   "answer": "Amgen Inc. (AMGN) has a price-to-sales ratio of 5.88, which is higher than the healthcare sector median of 3.7, suggesting it may be trading at a premium relative to its peers."
  },
  {
   "question": "What is Amgen Inc.'s recent earnings performance?",
   "answer": "In the quarter ending June 2026, Amgen Inc. (AMGN) reported an EPS of $6.29, beating estimates by 11.92% and leading to a positive stock price reaction. The company has shown a generally positive earnings surprise trend recently."
  },
  {
   "question": "Are Amgen Inc. insiders buying or selling stock?",
   "answer": "Insiders at Amgen Inc. (AMGN) are net sellers, with $30.4 million in total sales and no reported purchases in recent filings. This is classified as a 'Moderate Sell Signal'."
  },
  {
   "question": "What are the key technical indicators for AMGN stock?",
   "answer": "Amgen Inc. (AMGN) is trading above its 50-day and 200-day moving averages ($404.70 and $362.12), indicating a positive trend. The RSI is neutral at 40.35, and the MACD is slightly negative, suggesting a consolidation phase with limited immediate upside momentum."
  },
  {
   "question": "What is Amgen Inc.'s long-range stock projection for 2030?",
   "answer": "Based on Monte Carlo simulations, Amgen Inc. (AMGN) has a base case projection of $568.90 for 2030, with a downside projection of $297.80 and an upside projection of $1086.77. These are statistical outcomes, not guarantees."
  },
  {
   "question": "What is Amgen Inc.'s dividend yield?",
   "answer": "Amgen Inc. (AMGN) currently offers a dividend yield of approximately 2.40%."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "TLRY",
    "name": "Tilray Brands Inc. NASDAQ",
    "price": "$4.13",
    "change": "+1.47%",
    "url": "https://clearank.com/stock/tilray-brands-tlry/"
   },
   {
    "ticker": "VKTX",
    "name": "Viking Therapeutics, Inc. NASDAQ",
    "price": "$35.56",
    "change": "-3.24%",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   },
   {
    "ticker": "DXCM",
    "name": "DexCom Inc. NASDAQ",
    "price": "$86.62",
    "change": "-0.97%",
    "url": "https://clearank.com/stock/dxcm-stock-analysis/"
   },
   {
    "ticker": "BSX",
    "name": "Boston Scientific Corp. NYSE",
    "price": "$43.92",
    "change": "-1.70%",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "CNC",
    "name": "Centene Corp. NYSE",
    "price": "$61.82",
    "change": "-0.16%",
    "url": "https://clearank.com/stock/centene-cnc/"
   },
   {
    "ticker": "VRTX",
    "name": "Vertex Pharmaceuticals Incorporated NASDAQ",
    "price": "$526.19",
    "change": "+0.73%",
    "url": "https://clearank.com/stock/vertex-vrtx/"
   },
   {
    "ticker": "LLY",
    "name": "Eli Lilly and Company NYSE",
    "price": "$1,183.46",
    "change": "+0.13%",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "OSCR",
    "name": "Oscar Health, Inc. NYSE",
    "price": "$29.60",
    "change": "+2.53%",
    "url": "https://clearank.com/stock/oscr-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "USB vs PNC Comparison",
    "name": "",
    "url": "https://clearank.com/compare/usb-vs-pnc/"
   },
   {
    "ticker": "EOG vs DVN Comparison",
    "name": "",
    "url": "https://clearank.com/compare/eog-vs-dvn/"
   },
   {
    "ticker": "VUG vs VOOG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vug-vs-voog/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "VRSK",
    "text": "Verisk Analytics, Inc.",
    "url": "https://clearank.com/stock/vrsk-stock-analysis/"
   },
   {
    "ticker": "DEO",
    "text": "Diageo plc Sponsored",
    "url": "https://clearank.com/stock/deo-stock-analysis/"
   },
   {
    "ticker": "KMB",
    "text": "Kimberly-Clark Corporation",
    "url": "https://clearank.com/stock/kmb-stock-analysis/"
   },
   {
    "ticker": "IAUM",
    "text": "iShares Gold Trust Micro",
    "url": "https://clearank.com/etf/iaum-etf-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "SUI/USD",
    "text": "↑ 11.97%",
    "url": "https://clearank.com/crypto/sui-sui-usd/"
   },
   {
    "ticker": "KAS/USD",
    "text": "↑ 11.85%",
    "url": "https://clearank.com/crypto/kaspa-kas-usd/"
   },
   {
    "ticker": "RENDER/USD",
    "text": "↑ 10.19%",
    "url": "https://clearank.com/crypto/render-render-usd/"
   },
   {
    "ticker": "ZS",
    "text": "↓ 10.06%",
    "url": "https://clearank.com/stock/zscaler-zs/"
   },
   {
    "ticker": "MXL",
    "text": "↑ 10.00%",
    "url": "https://clearank.com/stock/mxl-stock-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "ABBV",
    "text": "AbbVie",
    "url": "https://clearank.com/stock/abbvie-abbv/"
   },
   {
    "ticker": "BIIB",
    "text": "Biogen Inc.",
    "url": "https://clearank.com/stock/biib-stock-analysis/"
   },
   {
    "ticker": "BMY",
    "text": "Bristol-Myers Squibb",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
   },
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "JNJ",
    "text": "Johnson & Johnson",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/amgn-amgen.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/amgn-amgen.png",
     "width": "1280",
     "height": "720",
     "caption": "Amgen (AMGN) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/amgen-amgn/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/amgen-amgn/",
        "name": "Amgen (AMGN) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/amgen-amgn/#webpage",
     "url": "https://clearank.com/stock/amgen-amgn/",
     "name": "Amgen (AMGN) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-12T09:10:32+00:00",
     "dateModified": "2026-09-27T08:41:15+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/amgn-amgen.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/amgen-amgn/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/amgen-amgn/#richSnippet",
     "headline": "Amgen (AMGN) Stock Forecast & Price Target (2026)",
     "name": "Amgen (AMGN) Stock Forecast & Price Target (2026)",
     "description": "Amgen Inc. (AMGN) stock: Healthcare, Drug Manufacturers - General. $224.2B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-06-12T09:10:32+00:00",
     "dateModified": "2026-09-27T08:41:15+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Amgen Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "AMGN"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and commercializes human therapeutics. Its current portfolio focuses on serious diseases across oncology, cardiovascular disease, inflammation, bone health, nephrology, and rare diseases, with medicines delivered th",
      "tickerSymbol": "AMGN",
      "sameAs": "https://www.amgen.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/amgen-amgn/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/amgn-amgen.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/amgen-amgn/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Amgen Inc.'s current stock price and consensus rating?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Amgen Inc. (AMGN) is currently trading at $414.61 per share. The consensus rating among analysts is 'Hold', with a consensus score of 57 out of 100."
     }
    },
    {
     "@type": "Question",
     "name": "What is the median analyst price target for AMGN stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median analyst price target for Amgen Inc. (AMGN) is $395.00, which represents a -4.7% downside from its current trading price."
     }
    },
    {
     "@type": "Question",
     "name": "How does Amgen Inc.'s valuation compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Amgen Inc. (AMGN) has a price-to-sales ratio of 5.88, which is higher than the healthcare sector median of 3.7, suggesting it may be trading at a premium relative to its peers."
     }
    },
    {
     "@type": "Question",
     "name": "What is Amgen Inc.'s recent earnings performance?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "In the quarter ending June 2026, Amgen Inc. (AMGN) reported an EPS of $6.29, beating estimates by 11.92% and leading to a positive stock price reaction. The company has shown a generally positive earnings surprise trend recently."
     }
    },
    {
     "@type": "Question",
     "name": "Are Amgen Inc. insiders buying or selling stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insiders at Amgen Inc. (AMGN) are net sellers, with $30.4 million in total sales and no reported purchases across 89 transactions. This is classified as a 'Moderate Sell Signal'."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical indicators for AMGN stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Amgen Inc. (AMGN) is trading above its 50-day and 200-day SMAs, indicating a positive trend. The RSI is neutral at 40.35, and the MACD is slightly negative, suggesting a consolidation phase with limited immediate upside momentum."
     }
    },
    {
     "@type": "Question",
     "name": "What is Amgen Inc.'s long-range stock projection for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Amgen Inc. (AMGN) has a base case projection of $568.90 for 2030, with a downside projection of $297.80 and an upside projection of $1086.77. These are statistical outcomes, not guarantees."
     }
    },
    {
     "@type": "Question",
     "name": "What is Amgen Inc.'s dividend yield?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Amgen Inc. (AMGN) currently offers a dividend yield of approximately 2.40%."
     }
    }
   ]
  }
 ]
}